pravastatin has been researched along with Osteonecrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Jiang, Y; Li, P; Lin, N; Lu, C; Xu, Y; Zhang, H; Zhang, Y; Zhu, B | 1 |
| Asada, A; Iwaki, H; Iwakiri, K; Kaneshiro, Y; Kobayashi, A; Masada, T; Oda, Y; Takaoka, K | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M | 1 |
3 other study(ies) available for pravastatin and Osteonecrosis
| Article | Year |
|---|---|
Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARĪ³ expression and activating Wnt signaling pathway.
Topics: Adipogenesis; Adipose Tissue; Adrenal Cortex Hormones; Animals; beta Catenin; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Femur Head; Femur Head Necrosis; Fibrinolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Low Density Lipoprotein Receptor-Related Protein-5; Male; Methylprednisolone; Neovascularization, Physiologic; Osteogenesis; Osteonecrosis; PPAR gamma; Pravastatin; Rats; Rats, Wistar; Wnt Signaling Pathway; Wnt3A Protein | 2014 |
Effect of simvastatin on steroid-induced osteonecrosis evidenced by the serum lipid level and hepatic cytochrome P4503A in a rabbit model.
Topics: Animals; Cytochrome P-450 CYP3A; Female; Glucocorticoids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Liver; Methylprednisolone; Osteonecrosis; Pravastatin; Probucol; Rabbits; Simvastatin | 2008 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid | 2010 |